Investigating the Neural Correlates of Cognitive Function in Psychosis Patients and Non-Psychiatric Controls With Cannabis Use
Key facts
- Where
- Montreal, CanadaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 16 and 80 years old?
Source: NCT05445180, who can take part
Where in Canada
- Douglas Mental Health University InstituteMontreal, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Douglas Mental Health University Institute
- Trial code
- NCT05445180
- Record updated
- 15 September 2026
- Original description
Cognitive impairment is well established in people with psychosis and is associated with cannabis use. The current study will investigate the neurobiological basis of cognitive change associated with 28-days of cannabis abstinence in people with psychosis and non-psychiatric controls with cannabis use. Participants will be randomized to a cannabis abstinent group or a non-abstinent control group and will undergo magnetic resonance imaging at baseline and following 28-days of abstinence. This study will help characterize the neuropathophysiological processes underlying cognitive dysfunction associated with cannabis use and its recovery which may guide the development of novel interventions for problematic cannabis use.Read full original descriptionShow less
Investigating the Neural Correlates of Cognitive Function Associated With Cannabis Abstinence in Psychosis Patients and Non-Psychiatric Controls With Cannabis Use
Cognitive impairment is well established in people with psychosis and is associated with cannabis use. The current study will investigate the neurobiological basis of cognitive change associated with 28-days of cannabis abstinence in people with psychosis and non-psychiatric controls with cannabis use. Participants will be randomized to a cannabis abstinent group or a non-abstinent control group and will undergo magnetic resonance imaging at baseline and following 28-days of abstinence. This study will help characterize the neuropathophysiological processes underlying cognitive dysfunction associated with cannabis use and its recovery which may guide the development of novel interventions for problematic cannabis use.
Inclusion: Able to provide informed consent in English or French; Heavy cannabis use (defined as weekly cannabis use for at six months) and/or DSM-5 diagnosis of CUD; Have a Full-Scale IQ ≥ 75; Meet DSM-5 criteria for a psychotic disorder (psychosis patient arm only); Be an outpatient receiving a stable dose of medication(s) for at least two months (psychosis patient arm only); Clinically stable (as measured by the PANSS-6, total score <30) (psychosis patient arm only).
Exclusion: Taking psychotropic medication; Current medical diseases that requires hospitalization or regular monitoring; DSM-5 Axis 1 diagnosis (other than CUD) (non-psychiatric controls only); current SUD (other than CUD); MRI contraindications; Positive urine screen for psychoactive substances other than cannabis, nicotine, or caffeine; Current suicidal or homicidal ideation; Head injury requiring hospitalization or loss of consciousness > 5 minutes; Being pregnant.